Abstracts tagged "Lupus"

Abstract Number: 674 • 2014 ACR/ARHP Annual Meeting
A Novel Strategy to Identify and Evaluate Approved Drugs and Treatments for Repositioning As Therapies for Systemic Lupus Erythematosus (SLE)
Peter E. Lipsky, Matthew Ryals, Jacob Smearman, Victoria Soler and Amrie Grammer, AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Development of new SLE treatments has been slow with only one new treatment approved in the past half century. One way to increase the…
Abstract Number: 2643 • 2014 ACR/ARHP Annual Meeting
Angiogenic and Antiangiogenic Factors in Patients with Systemic Lupus Erythematosus
Guilherme Ramires de Jesus¹, Camila Souto Oliveira², Flavia Cunha dos Santos³, Nilson Ramires de Jesus³, Luis Cristovao Porto⁴, Roger A. Levy⁵ and Evandro Mendes Klumb⁶, ¹Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Rheumatology, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil, ³Obstetrics, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil, ⁴Immunology, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil, ⁵Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Background/Purpose SLE mainly affects young women and pregnancy in these patients has significant morbidity and mortality. Clinical and laboratory findings in lupus nephritis are similar…
Abstract Number: 1213 • 2014 ACR/ARHP Annual Meeting
Absence of Hormone Responsive Estrogen Receptor Alpha Reduces the Activation of Plasmacytoid Dendritic Cells in Lupus Prone Mice
Jennifer L. Scott¹, Melissa A. Cunningham², Osama S. Naga³, Jackie G. Eudaly³, Jena R. Wirth⁴ and Gary S. Gilkeson⁵, ¹Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, ²Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ³Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ⁴Med/Rheumatology, MUSC, Charleston, SC, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that affects women at a 9 to 1 ratio compared to men. To further understand…
Abstract Number: 668 • 2014 ACR/ARHP Annual Meeting
Evolution of Patients with Systemic Lupus Erythematous Treated with Belimumab in Clinical Practice Settings
Josefina Cortes¹, Carlos Marras², Jose Luis Andreu³, Jaime Calvo-Alen⁴, Angel M. Garcia-Aparicio⁵, Elvira Diez Alvarez⁶, Carlos Coronell⁷, Elena Morejon⁷, Alessandra Perna⁸, Volker Koscielny⁸ and Josep Ordi-Ros¹, ¹Internal Medicine, Vall d´Hebron Hospital, Barcelona, Spain, ²Rheumatology, Virgen de la Arrixaca Hospital, Murcia, Spain, ³Rheumatology, Puerta de Hierro Universitary Hospital, Madrid, Spain, ⁴Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, ⁵Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, ⁶Rheumatology, Leon Hospital, Leon, Spain, ⁷Medical Department, GlaxoSmithKline, Madrid, Spain, ⁸Medical Department, GlaxoSmithKline, Brentford, United Kingdom
Background/Purpose After the approval of belimumab for patients with systemic lupus erythematosus (SLE), the objective of this study is to describe the clinical outcomes associated…
Abstract Number: 2639 • 2014 ACR/ARHP Annual Meeting
Coronary-Artery Atherosclerosis in Males with Systemic Lupus Erythematosus
Juanita Romero-Díaz¹, Sergio Criales-Vera², Eric Kimura-Hayama², Roberto Ivan Acosta-Hernandez¹, Maricruz Dominguez-Quintana¹ and Jorge Sánchez-Guerrero³, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ²Radiology Department, Instituto Nacional de Cardiologia, Mexico City, Mexico, ³Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose . Premature coronary-artery atherosclerosis is a major cause of morbidity and mortality in females with systemic lupus erythematosus (SLE), but little is known about the…
Abstract Number: 1080 • 2014 ACR/ARHP Annual Meeting
Stroke Risks Among U.S. Medicaid Recipients with Systemic Lupus Erythematosus, 2000-2006: Racial and Ethnic Variation
Medha Barbhaiya¹, Jose A Gomez-Puerta², Hongshu Guan³, Daniel H. Solomon¹, Joanne M. Foody⁴, Graciela S. Alarcon⁵ and Karen H. Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, Boston, MA, ³Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, ⁵Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose SLE patients are at increased stroke risk, but racial/ethnic variation in risk has not been examined in a population-based study. We examined risks by…
Abstract Number: 664 • 2014 ACR/ARHP Annual Meeting
The Pathogenesis of Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Brain Intrinsic Factors
Ariel Stock¹, Jing Wen², Jessica Doerner² and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric disease is a common manifestation of systemic lupus erythematosus (SLE). Frequent presentations include depression, anxiety, memory loss and cognitive decline. The pathogenesis of…
Abstract Number: 2623 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns and Resource Utilization of Systemic Lupus Erythematosus Patients Newly Initiating Standard of Care: United States Commercial and Medicare Supplemental Claims Analysis
Shonda A Foster¹, Emily Durden², Brett Maiese², Sarah Al Sawah¹ and Kathleen Solotkin¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Truven Health Analytics, Bethesda, MD
Background/Purpose: Currently, there is not a standard treatment algorithm for the management of Systemic Lupus Erythematosus (SLE); however, there are medications that may be considered…
Abstract Number: 870 • 2014 ACR/ARHP Annual Meeting
IRF1 Influences on Histone H4 Acetylation in Systemic Lupus Erythematosus
Yiu Tak Leung¹, Lihua Shi², Kelly Maurer², Li Song², Zhe Zhang³, Michelle Petri⁴ and Kathleen E. Sullivan², ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Bioinformatics, Bioinformatics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is the classical systemic autoimmune disease. Epigenetic processes, such as posttranslational histone modifications, can regulate gene expression without altering the…
Abstract Number: 663 • 2014 ACR/ARHP Annual Meeting
STAT3 Inhibition Delays the Onset of Lupus Nephritis in MRL/Lpr Mice
Linsday Edwards¹ and Vasileios C. Kyttaris², ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ²Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose The transcription factor Signal transducer and activator of transcription (STAT) 3 is overexpressed and aberrantly activated in patients with SLE as well as lupus-prone…
Abstract Number: 2172 • 2014 ACR/ARHP Annual Meeting
PTPN22 Promotes TLR-Induced Amelioration of Arthritis
David Ewart¹, Erik J. Peterson¹ and Yaya Wang², ¹University of Minnesota, Minneapolis, MN, ²Center for Immunology, University of Minnesota, Minneapolis, MN
Background/Purpose: Rheumatoid arthritis (RA) synovial fluid exhibits high levels of type 1 interferons (IFN). Type 1 IFN may exert potent anti-inflammatory effects, since a TLR3…
Abstract Number: 864 • 2014 ACR/ARHP Annual Meeting
Association of Coronary Artery Calcification with Brown and White Pericardial Adipose Tissue in SLE
Kelly J. Shields, Medicine, Lupus Center of Excellence / Allegheny Health Network, Pittsburgh, PA
Background/Purpose Women with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD). We have shown that clinically CVD-free women with SLE have…
Abstract Number: 655 • 2014 ACR/ARHP Annual Meeting
Hydroxycholorquine Is Cardioprotective in an In Vivo Rat Model of Myocardial Ischaemic Reperfusion Injury
Lauren Bourke^1,2, Valerie Taylor³, James McCormick⁴, Charis Pericelous¹, John Franklin¹, Daniel Stuckey³, Mark Lythgoe⁵, Anastasis Stephanou⁶ and Yiannis Ioannou^2,7, ¹Centre for Rheumatology Research, University College London, London, United Kingdom, ²Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ³Centre for Advanced Biomedical Imaging (CABI), University College London, London, United Kingdom, ⁴Clinical & Molecular Genetics Unit, University College London, London, United Kingdom, ⁵Centre for Advanced Biomedical Imaging, Centre for Advanced Biomedical Imaging (CABI), University College London, London, United Kingdom, ⁶Medical and Molecular Biology Unit (MMBU), University College London, London, United Kingdom, ⁷Centre for Rheumatology Research, University College Hospital London, London, United Kingdom
Background/Purpose A significant amount of myocardial damage during a myocardial infarction (MI) occurs during the reperfusion stage which is known as ischaemic reperfusion (I/R) injury…
Abstract Number: 2007 • 2014 ACR/ARHP Annual Meeting
Using Photovoice Techniques to Empower Lupus Patients and Create Public Awareness: A Program Evaluation
Jessica Rowshandel and Diane Gross, S.L.E. Lupus Foundation, New York, NY
Background/Purpose: Lupus through the Lens is a photography project for people with lupus to capture, in pictures, what it means to live with lupus. Created…
Abstract Number: 863 • 2014 ACR/ARHP Annual Meeting
Metabolic Syndrome in Young Premenopausal Female Lupus Patients Is Mainly Influenced By Therapies
Luciana Muniz¹, Rosa M.R. Pereira², Thiago Silva³, Eloisa Bonfá⁴ and Eduardo Ferreira Borba¹, ¹Rheumatology Division, University of São Paulo, São Paulo, Brazil, ²Rheumatology, University of São Paulo, São Paulo, Brazil, ³Rheumatology Division, University of Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: A high prevalence of metabolic syndrome (MetS) has been observed in Systemic Lupus Erythematosus (SLE) patients, but there are scarce data about the main…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].